News Release

Adamis CEO Dr. Dennis J. Carlo to Present at the LD Micro Invitational
SAN DIEGO, CA -- (Marketwired) -- 06/04/14 --   Adamis
Pharmaceuticals Corporation (NASDAQ: ADMP) announced it will present
at the LD Micro Invitational Conference today at the Luxe Sunset
Boulevard Hotel in Los Angeles. 
The Company's presentation by Dr. Dennis Carlo, President and CEO,
will begin at 11:00 a.m. PDT. Dr. Carlo will provide an update on the
Company's specialty pharmaceutical programs including its recently
filed NDA for epinephrine injection. 
About LD Mirco 
LD Micro is a newsletter firm that focuses on finding undervalued
companies in the mirco-cap space. The conference hosts 100 companies
and provides them with the opportunity to showcase to quality private
and institutional investors. For more information on the conference
please visit 
About Adamis Pharmaceuticals Corporation 
Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical
company focused on developing and commercializing products in the
therapeutic areas of respiratory disease, allergy, oncology and
immunology. The company's current specialty pharmaceutical product
candidates include the Epinephrine Injection PFS syringe product for
use in the emergency treatment of anaphylaxis, APC-1000 and APC-5000
for the treatment of asthma and chronic obstructive pulmonary
disease, and APC-3000, an HFA inhaled nasal steroid product for the
treatment of allergic rhinitis. The company's vaccine product
candidates and cancer drug product candidates under research and
development include TeloB-VAX, a cell-based therapeutic cancer
vaccine and three drugs, APC-100, APC-200, and APC-300, for the
treatment of prostate cancer. 
Mark Flather
Director, Investor Relations &
Corporate Communications
Adamis Pharmaceuticals Corporation
(858) 412-7951